Manufacturer record

YL Pharma: regulatory record

Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories

9 batches manufactured by YL Pharma (Himachal Pradesh) were declared Not of Standard Quality between September 2025 and February 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.

Records by type

9 records linked to YL Pharma in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.

0Banned or prohibited
0Recalled or suspended
9Failed a lab test
0Regulatory notice
Primary government sourceTier 1: government primary source

CDSCO drug alerts: Not of Standard Quality and spurious drugs

CDSCO · CDSCO monthly NSQ alerts, Sep 2025 to Feb 2026

View original document

Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.

9
NSQ batches since 2025
6
Products affected
Assay
Most common failure
Feb 2026
Latest alert

Flagged batches per year

2025 · 82026 · 1

All flagged batches

Product Batch Reason declared NSQ Tested by Alert
Paracetamol, Phenylephrine Hydrochloride Diphenhydramine, Hydrocloride & Caffeine Tablets YLT25023Mfg 2025-06 · Exp 2027-05 The sample does not conform to the claim with respect to in Assay of Phenylephrine Hydrochloride & Caffeine (Anhydrous) (NIL).Assay DTL JaipurState lab Feb 2026
Levocetirizine Dihydrochloride & Montelukast Sodium Tablets IP LT-25029Mfg 2025-09 · Exp 2027-08 The sample does not HP conform to the IP with respect to Assay.Assay DTL, JaipurState lab Dec 2025
Levocetirizine Dihydrochloride Tablets YLT25023Mfg 2025-03 · Exp 2027-02 The sample does not conform to the IP with respect to AssayAssay DTL, JaipurState lab Dec 2025
Diclofenac Potassium & Paracetamol Tablets (MUSCARE-P TAB.) YLT25027Mfg 2025-07 · Exp 2027-06 Diclofeanc Potassium Assay 83.54% & Assay Of Paracetamol 79.83%Assay DTL BADDIState lab Dec 2025
Ofloxacin Tab IP 200mg YLT25025Mfg 2025-06 · Exp 2027-05 The Sample Does not conform to the IP with respect to AssayAssay DTL, JaipurState lab Nov 2025
Levocetirizine Dihydrochloride & Montelukast Sodium Tablets YLT25029Mfg 2025-09 · Exp 2027-08 The Sample Does not conform to the IP with respect to AssayAssay DTL, JaipurState lab Nov 2025
Levocetirizine DiHydrochloride Tablets YLT25028Mfg 2025-07 · Exp 2027-06 The Sample Does not conform to the IP with respect to AssayAssay DTL, JaipurState lab Nov 2025
Levocetirizine Dihydrochloride Tab (Wineet-L) YLT25023Mfg 2025-03 · Exp 2027-02 The sample does not conform to the IP as it does not contain Levocetirizine DihydrochlorideOther DTL, JaipurState lab Oct 2025
Paracetamol, Phenylephrine Hcl, Caffeine & Diphenhydramine Hcl Tablets YLT25006Mfg 2025-01 · Exp 2026-12 Identification & AssayAssay DTL ,Baddi, HPState lab Sep 2025

Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.